The measurement of serum inorganic phosphorus by direct acidl molybdate assay is known to be subject to interference by some serum paraproteins. Serum samples from 45 paraproteinaemic patients were used for the measurement of inorganic phosphorus using a manufacturer's kit reagent and a detergent-modified reagent from the same manufacturer. In addition, the same samples were analysed with both reagents following precipitation of serum protein with trichloroacetic acid. Using the original reagent pseudohyperphosphataemia was found in 27ftJo (12/45) of the samples. The modified reagent was free from interference with no significant difference between results from serum and protein-free supernatants.
Pseudohyperphosphataemia has been reported previously in patients with paraproteins. Some studies have shown that interference is due to turbidity caused by precipitation of the paraprotein by the acid reagent used in both visible and ultra-violet spectrophotometric methods.l:'! Other workers have identified the presence of a phosphate binding immunoglobulin.P:"! The Boehringer Mannheim (BM UK Ltd, Sussex, UK) method for inorganic phosphorus (Product No. 1040898) is known to be subject to interference in some patients with paraproteins." The manufacturer's claim that interference has been reduced significantly by a recent change in reagent composition.
We have compared the performance of the two reagent kits in samples from 45 patients with paraproteinaemia using whole serum and proteinfree supernatants of the same serum.
MATERIALS AND METHODS
Blood samples from 45 patients in whom paraproteins had previously been identified by electrophoresis and typing by immunofixation were obtained for diagnosis or treatment monitoring.
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The study included samples with IgG (n = 36, range 8-80 giL), IgA (n = 5, range 11-28 giL) and IgM (n = 4, range 10-33 giL) paraproteins. Aliquots of serum were stored at -20°C prior to analysis.
Serum inorganic phosphorus was measured on an Hitachi 717 using two kits (BM Cat No. 1040898) of different lot numbers. Kit X (Lot No. 645386) was the original formulation, and Kit Y (Lot No. 650415) contained the modified reagent. Serum was diluted with sulphuric acid and the blank absorbance measured at 340 nm and 376 nm. On addition of ammonium molybdate, inorganic phosphorus is converted to ammonium phosphomolybdate which is measured at 340 and 376 nm. The final concentrations were: molybdate 1·0 mmol/L, sulphuric acid 0·35 mol/L, sodium chloride 44 mmol/L and detergent. Kits X and Y differed in detergent composition, the details of which have not been disclosed by the manufacturers.
The same serum samples were analysed using both reagents after precipitation of protein using equal volumes of serum and 0·61 mol/L trichloracetic acid, the method currently in use in this laboratory when hyperphosphataemia is found in patients with paraproteins. The supernatant was analysed directly following centrifugation.
Inorganic phosphorus was also measured using both reagents in serum samples from 37 nonparaprotein patients. 
-0·005 NS SD = Standard deviation; NS = not significant; PFS = protein-free supernatants.
Paraprotein concentration was determined by scanning densitometry of the cellulose acetate electrophoretic separation and measurement of total protein concentration. The paired t test was used to assess significant differences between results obtained by the two kits.
RESULTS
Results from the two methods using serum and protein-free supernatants are shown in Table I . The mean serum inorganic phosphorus concentration from Kit X was significantly higher than the mean from Kit Y. There was no significant difference between the mean serum inorganic phosphorus concentration from Kit Y and the mean concentration using protein-free supernatants from Kit X or Kit Y. There was no significant difference between inorganic phosphorus results from serum and protein-free filtrates using Kit X for patients without monoclonal proteins (mean -I ·244 mmollL versus I· 255 mmollL, n = 16, P= O·3).
In 12 of the 45 patients (27070), results using Kit X were flagged by the instrument due to atypical absorbance changes caused by turbidity on addition of the second reagent. The flag was obtained by entering a 'prozone limit value' in the instrument chemistry parameter settings to an upper limit of 10070, as suggested by BM UK Ltd. In a normal serum there was a very small absorbance increase following the addition of sulphuric acid. After the addition of ammonium molybdate maximum absorbance was reached within one minute. In some paraproteinaemic samples turbidity increased gradually during both phases of the reaction using Kit X and an endpoint was not reached. This effect was not seen using Kit Y. The reaction traces for both kits are shown in Fig. I for a serum paraprotein where the inorganic phosphorus result was flagged using Kit X but was not flagged using Kit Y. When the 12 samples with flagged results were excluded, there was a trivial but statistically significant difference (P = 0·007) between the mean serum inorganic phosphorus concentration for the two kits (Kit X = 1·173 mmollL, Kit Y = 1·151 mmoIlL). The discrepancy between inorganic phosphorus concentration in serum and the protein-free supernatant using Kit X was most marked in those samples with the highest paraprotein concentration (Fig. 2) .
All 12 samples with flagged results contained an IgG paraprotein. The mean paraprotein concentration in this group (47' 1 giL, range 24-80 giL) was significantly higher (P= <0'01) than the mean concentration in the remaining 33 sera (20' 3 giL, range 8-48 giL).
In samples from 37 patients without paraproteins there was a trivial but statistically significant difference (P=0'OO7) between the mean serum inorganic phosphoruss concentration by the two methods (Kit X = 1. 047 mmol/L, Kit Y = 1·058 mmol/L).
DISCUSSION
Pseudohyperphosphataemia due to interference by serum paraprotein in a spectrophotometric method was first described in 1986. 1 -3 In these three reports, interference occurred in the presence of an IgG paraprotein. Since then, there have been several reports of pseudohyperphosphataemia due to acid precipitation of IgG, IgA and IgM paraproteins.v " Other workers, however, have presented evidence of increased binding of inorganic phosphorus by monoclonal IgG. 13 -15 In this study, it has been demonstrated that turbidity in the reaction mixture is the cause of pseudohyperphosphataemia using the original reagent formulation (Kit X), and was found in 270/0 of the paraprotein sera analysed. Where interference was present all samples contained an IgG paraprotein and in general there was a positive correlation between the paraprotein concentration and the degree of interference. Falsely elevated concentrations of inorganic phosphorus were not seen in samples containing IgA or IgM paraproteins, but only a small number of these was available for study, and mean paraprotein concentrations were lower than in IgG paraproteinaemics.
Pseudohyperphosphataemia was defined in this study by an instrument flag (prozone limit) which detects atypical absorbance changes on the addition of ammonium molybdate reagent. In previous reports where a series of patient samples was investigated, different criteria for pseudohyperphosphataemia were used, 6, 9, 11, 12 and this may explain the variable incidence (8-49%) of this phenomenon.
Bowles and co-workers'? suggested that Ann ctt« Biochem 1995: 32 interference is more common in IgG paraproteinaemics due to the lower carbohydrate content of this immunoglobulin, but presented no evidencefor this. Other physicochemical differences between immunoglobulin classes may explain the higher incidence of pseudohyperphosphataemia in the presence of monoclonal IgG. We found no difference between results for inorganic phosphorus on whole serum and protein-free supernatants in samples from patients with paraproteins using Kit Y. The modified reagent formulation has been used routinely in this laboratory for 6 months and no results have been flagged during this period. We conclude that the modified reagent formulation is free from interference due to paraprotein and furnishes reliable results.
